Effect of tolvaptan in patients with chronic kidney disease due to diabetic nephropathy with heart failure
| Autor: | Yuko Ono, Tsukasa Nakamura, Daisuke Matsumura, Mayumi Nomura, Eiichi Sato, Yoshihiko Ueda, Mayuko Amaha, Hidetsugu Yamagishi |
|---|---|
| Rok vydání: | 2014 |
| Předmět: |
Male
medicine.medical_specialty Nephrotic Syndrome Tolvaptan Urology Kidney Diabetic nephropathy medicine Humans Diabetic Nephropathies Aged Retrospective Studies Aged 80 and over Heart Failure Aquaporin 2 business.industry Kidney metabolism Glomerulosclerosis General Medicine Benzazepines Middle Aged medicine.disease medicine.anatomical_structure Heart failure Female Cardiology and Cardiovascular Medicine business Nephrotic syndrome Antidiuretic Hormone Receptor Antagonists Kidney disease medicine.drug |
| Zdroj: | International heart journal. 55(6) |
| ISSN: | 1349-3299 |
| Popis: | The efficacy of tolvaptan for treating heart failure has already been shown. Adequate data relating to the effect of tolvaptan on the correlation of water balance in renal disease are not available. A retrospective study was conducted on the efficacy and adverse reactions of tolvaptan for treating nephrotic syndrome.The subjects were 26 patients with chronic kidney failure due to diabetic nephropathy with heart failure who were administered tolvaptan and seen between December 2011 and October 2013. The endpoints were urinary output, physical findings, and blood analyses. The expression of aquaporin-2 in the collecting duct, which is related to the action of tolvaptan, was investigated by immunohistochemistry using the kidney tissue obtained for the diagnosis.Responses were seen in 19 of the patients. In the histopathological investigation there was severe glomerulosclerosis in patients with diabetic nephropathy, but the responders were noticeable in that they only had mild tubulointerstitial damage. Non-responders exhibited profound tubulointerstitial damage. The expression of aquaporin-2 was determined in 8 patients, of which 7 were responders who tested positive for aquaporin-2. The remaining case was a non-responder who showed no expression of aquaporin-2.Tolvaptan is considered effective for some cases of nephrotic syndrome. There are no clear parameters for predicting an effect, but the present study showed that aquaporin-2 was expressed in the epithelial cells of the collecting ducts of tolvaptan responders. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|